Alina Gerrie

Prospective Graduate Students / Postdocs

This faculty member is currently not actively recruiting graduate students or Postdoctoral Fellows, but might consider co-supervision together with another faculty member.

Assistant Professor

Research Classification

Research Interests

Lymphoid Cancer
Population-based outcomes
Cellular therapy
Quality of life

Relevant Thesis-Based Degree Programs

Affiliations to Research Centres, Institutes & Clusters

Research Options

I am available and interested in collaborations (e.g. clusters, grants).
I am interested in and conduct interdisciplinary research.
I am interested in working with undergraduate students on research projects.

Graduate Student Supervision

Master's Student Supervision

Theses completed in 2010 or later are listed below. Please note that there is a 6-12 month delay to add the latest theses.

Real-world characterization of ibrutinib therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma in British Columbia (2022)

Background: Ibrutinib therapy has quickly become standard of care in Canada for CLL/SLL patients, due to its proven survival benefits. Real-world studies, however, have unveiled that ibrutinib therapy is also associated with higher rates of discontinuations and toxicities in patients. It is predicted that patients on ibrutinib therapy incur high costs to the healthcare system due to these toxicities. One potential solution includes testing for immunoglobulin heavy chain variable region (IGHV) mutations. IGHV has the potential to inform treatment-decisions, allowing for the appropriate administration of ibrutinib and improved outcomes in patients.Objectives: The global objective was to complete a comprehensive real-world population-level observational study to characterize ibrutinib treatment in CLL/SLL patients in BC. The specific aims were as follows: i) to assess the rates of adverse events, discontinuations, dose modifications, and survival outcomes ii) to characterize the healthcare utilization and associated costs of ibrutinib therapy, and iii) to assess the impact of IGHV genomic testing, costs, resource use, and challenges of this testing and impact on survival.Methods: Provincial cancer and administrative databases were used to collate the data required. Each objective was addressed using three unique cohorts. Specific inclusion and exclusion criteria were set, and strict data cleaning procedures were followed.Results: Ibrutinib therapy led to good survival outcomes in the first-line and relapse/refractory settings; however, a high proportion of patients (35.1%) discontinued their ibrutinib treatment due to toxicities or disease progression. Survival outcomes were not maintained for patients who discontinued treatment regardless of reason. In the first 3 years of its use, ibrutinib cost a mean of $68,266.31 per patient per year. From time of diagnosis, patients with unmutated IGHV had worse overall survival (OS) compared to patients with mutated IGHV (P
View record


Membership Status

Partner appointment
View explanation of statuses


BC Cancer Agency

Program Affiliations

Academic Unit(s)


If this is your researcher profile you can log in to the Faculty & Staff portal to update your details and provide recruitment preferences.


Explore our wide range of course-based and research-based program options!